Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of Less Invasive Surfactant Administration in Preterm Infants: A Meta-Analysis.

Pediatric pulmonology·2026
Same author

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.

European urology oncology·2026
Same author

Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment.

JCO precision oncology·2026
Same author

Efficacy of Less Invasive Surfactant Administration (LISA) in Preterm Neonates With Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.

Sage open pediatrics·2026
Same author

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Nature medicine·2026
Same author

Caulobacter crescentus harbours an evolutionarily distinct UDG (CC2084), UdgC, sharing features with family I and family V UDGs.

DNA repair·2026
Same journal

Identification of a Novel <i>GOLGB1-RET</i> Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

JCO precision oncology·2026
Same journal

Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma.

JCO precision oncology·2026
Same journal

Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.

JCO precision oncology·2026
Same journal

Complete Response to Immune Checkpoint Inhibitor-Based Combination Therapy in PD-L1-High, Tumor Mutational Burden-Low Ovarian Sarcomatoid Squamous Cell Carcinoma.

JCO precision oncology·2026
Same journal

Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical <i>EGFR</i> Mutation: A Molecular Tumor Board Discussion.

JCO precision oncology·2026
Same journal

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

JCO precision oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K

Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection.

James Yu1, Aiwu Ruth He2, Mahmoud Ouf2

  • 1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.

JCO Precision Oncology
|January 8, 2025
PubMed
Summary
This summary is machine-generated.

Circulating tumor DNA (ctDNA) shows prognostic value for relapse and can detect recurrence earlier than standard surveillance in early-stage biliary tract cancer (BTC) patients after curative resection.

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

10.9K
Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
05:22

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

12.0K

Related Experiment Videos

Last Updated: Jun 3, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

10.9K
Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
05:22

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

12.0K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Cancer Biomarkers

Background:

  • Biliary tract cancer (BTC) is a group of aggressive malignancies.
  • Early-stage BTC treated with curative intent requires effective surveillance for recurrence.
  • Standard surveillance methods may have limitations in early detection.

Purpose of the Study:

  • To evaluate the prognostic significance of circulating tumor DNA (ctDNA) in patients with curatively resected early-stage BTC.
  • To assess the capability of ctDNA testing to detect recurrence earlier than conventional surveillance strategies.
  • To compare the efficacy of ctDNA surveillance against standard methods for relapse detection in BTC.

Main Methods:

  • Retrospective, multicenter cohort study design.
  • Serial ctDNA testing was performed for surveillance in patients with early-stage BTC post-curative resection.
  • Relapse-free survival (RFS) was analyzed based on ctDNA positivity; sensitivity for recurrence detection and lead time were calculated.

Main Results:

  • ctDNA detection was significantly associated with poorer RFS during both the molecular residual disease and surveillance periods.
  • ctDNA identified recurrence in 93.8% of patients with a confirmed recurrence, with an average lead time of 3.7 months.
  • Unlike ctDNA, carbohydrate antigen 19-9 levels did not show a significant correlation with RFS.

Conclusions:

  • ctDNA demonstrates promising prognostic value as a biomarker for predicting relapse in curatively resected BTC.
  • ctDNA holds potential for earlier detection of recurrence compared to standard surveillance methods in BTC.
  • These findings support the clinical utility of ctDNA in monitoring patients with early-stage BTC after curative treatment.